New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: FelCor Lodging Trust Incorporated (NYSE:FCH), Corinthian Colleges Inc (NASDAQ:COCO), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
FelCor Lodging Trust Incorporated (NYSE:FCH) showed a volume of 2.33 million shares by the end of last trade whereas the average volume of the stock remained 658,109.00 shares. The stock opened the session at $8.18 but then moved to $8.52. At that price, the stock showed a positive performance of 5.45%. FelCor Lodging Trust Incorporated is a real estate investment trust (REIT). FelCor is the sole general partner of, and the owner of a greater than 99% partnership interest in, FelCor Lodging Limited Partnership (FelCor LP), through which the Company held ownership interests in 66 hotels with 18,993 rooms as of December 31, 2012. The Company’s core portfolio consists primarily of upper-upscale hotels and resorts located in markets and resort locations that have dynamic demand generators and high barriers to entry. Most of the Company’s hotels are operated under brands, such as Doubletree, Embassy Suites, Fairmont,
Will FCH Continue To Move Higher? Find Out Here
Corinthian Colleges Inc (NASDAQ:COCO) opened the session at $1.63 and closed the session at $1.64. The stock showed a negative performance of -1.80% in previous trading session. Traded with volume of 2.32 million shares in the prior session and the average volume of the stock remained 1.34 million shares. Corinthian Colleges, Inc. is a post-secondary education company in the United States and Canada. As of June 30, 2013, the Company had a student enrollment of 81,284 and operated 97 schools in 25 states, and 14 schools in the province of Ontario, Canada. It offers a variety of diploma programs and associate, bachelor's and master's degrees. The Company’s training program areas include healthcare, criminal justice, business, mechanical, trades, and information technology. The Company’s diploma curricula includes medical assisting, medical insurance billing and coding, massage therapy, dental assisting,
Has COCO Found The Bottom And Ready To Gain Momentum? Find Out Here
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) opened the session at 5.85 and closed the session at $5.87. The stock showed a positive performance of 1.03% in previous trading session. Traded with volume of 2.31 million shares in the prior session and the average volume of the stock remained 2.51 million shares. Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company’s product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. The Company’s Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data.
Why Should Investors Buy MACK After The Recent Gain? Just Go Here and Find Out
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) the stock decreased -0.62% and finished the session at $0.974. Traded with volume of 2.30 million shares in the prior session and the average volume of the stock remained 4.21 million shares. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company’s products include ICT-107, ICT-140, ICT-121, ICT-109 and DIAAD. ICT-107,
Will IMUC Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)